To do this, we used, in addition to the prostate cancer cell line PC3, the hepatoma cell line HepG2 and the breast cancer cell line MDA-MB 231 in which we eliminated CDK5 by using the CRISPR-Cas9 technique (Figure 3A). This evidence concerns the gene CDK5 and breast carcinoma.